0.7502
price down icon0.64%   -0.0048
 
loading
前日終値:
$0.755
開ける:
$0.7466
24時間の取引高:
56,158
Relative Volume:
0.02
時価総額:
$42.89M
収益:
-
当期純損益:
$-81.22M
株価収益率:
-0.2534
EPS:
-2.96
ネットキャッシュフロー:
$-74.41M
1週間 パフォーマンス:
-9.45%
1か月 パフォーマンス:
+2.60%
6か月 パフォーマンス:
-43.17%
1年 パフォーマンス:
-28.55%
1日の値動き範囲:
Value
$0.7466
$0.7784
1週間の範囲:
Value
$0.7143
$0.84
52週間の値動き範囲:
Value
$0.62
$1.70

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name
名前
Xilio Therapeutics Inc
Name
セクター
Healthcare (1152)
Name
電話
617-833-1027
Name
住所
828 WINTER STREET, WALTHAM
Name
職員
73
Name
Twitter
Name
次回の収益日
2024-11-09
Name
最新のSEC提出書
Name
XLO's Discussions on Twitter

XLO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
XLO
Xilio Therapeutics Inc
0.7502 42.89M 0 -81.22M -74.41M -2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-12-21 開始されました Chardan Capital Markets Buy
2022-01-10 開始されました H.C. Wainwright Buy
2021-11-16 開始されました Cowen Outperform
2021-11-16 開始されました Guggenheim Buy
2021-11-16 開始されました Morgan Stanley Overweight
2021-11-16 開始されました Raymond James Outperform
すべてを表示

Xilio Therapeutics Inc (XLO) 最新ニュース

pulisher
May 03, 2025

Geode Capital Management LLC Acquires 20,230 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World

May 03, 2025
pulisher
May 02, 2025

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

Xilio Therapeutics Awards 5,000 Share Stock Option Grant at $0.755 Per Share to New Employee - Stock Titan

May 02, 2025
pulisher
May 01, 2025

Xilio’s Stacey Davis recruited by Enara - The Pharma Letter

May 01, 2025
pulisher
Apr 23, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Xilio Therapeutics Announces Presentation of Phase 2 Data for Vilastobart and Atezolizumab at 2025 ASCO Annual Meeting - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Phase 2 Trial Results: Novel Tumor-Activated Therapy Shows Promise in Hard-to-Treat Colorectal Cancer - Stock Titan

Apr 23, 2025
pulisher
Apr 14, 2025

50,086 Shares in Xilio Therapeutics, Inc. (NASDAQ:XLO) Bought by Raymond James Financial Inc. - Defense World

Apr 14, 2025
pulisher
Apr 09, 2025

Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India

Apr 09, 2025
pulisher
Apr 08, 2025

Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 05, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 05, 2025
pulisher
Apr 04, 2025

Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan

Apr 04, 2025
pulisher
Apr 02, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday - Defense World

Mar 31, 2025
pulisher
Mar 25, 2025

Head to Head Contrast: Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) - Defense World

Mar 25, 2025
pulisher
Mar 20, 2025

Deals In Depth: February 2025 - insights.citeline.com

Mar 20, 2025
pulisher
Mar 18, 2025

Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Mar 18, 2025
pulisher
Mar 13, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK

Mar 11, 2025
pulisher
Mar 11, 2025

Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com

Mar 11, 2025
pulisher
Mar 11, 2025

Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Xilio Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025 - Nasdaq

Mar 11, 2025
pulisher
Mar 04, 2025

Insider Sale Alert: Xilio Therapeutics Inc [XLO] – Is it Time to sell? - Knox Daily

Mar 04, 2025
pulisher
Feb 28, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World

Feb 28, 2025
pulisher
Feb 24, 2025

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan

Feb 24, 2025
pulisher
Feb 22, 2025

Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN

Feb 20, 2025
pulisher
Feb 19, 2025

Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle

Feb 19, 2025
pulisher
Feb 18, 2025

Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com

Feb 18, 2025
pulisher
Feb 17, 2025

Top Biotech Stocks To Keep An Eye OnFebruary 12th - MarketBeat

Feb 17, 2025
pulisher
Feb 14, 2025

Stock summary: Xilio Therapeutics ended the week with a surge of 70.12% - Business Upturn

Feb 14, 2025
pulisher
Feb 14, 2025

Latham Advises AbbVie on Collaboration and Option Agreement With Xilio Therapeutics and Related Equity Investment - Latham & Watkins LLP

Feb 14, 2025
pulisher
Feb 14, 2025

Xilio shares soar on AbbVie collaboration deal - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE

Feb 14, 2025
pulisher
Feb 14, 2025

Top Biotech Stocks To Keep An Eye On – February 12th - Defense World

Feb 14, 2025
pulisher
Feb 13, 2025

AbbVie Deal Unmasks Promise Of Xilio’s T-Cell Engagers - News & Insights

Feb 13, 2025

Xilio Therapeutics Inc (XLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Xilio Therapeutics Inc (XLO) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Brennan Kevin M.
SVP, FINANCE AND ACCOUNTING
Jan 02 '25
Sale
0.98
1,803
1,774
3,197
GILEAD SCIENCES, INC.
10% Owner
Dec 18 '24
Buy
1.04
1,759,978
1,830,377
9,105,451
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
大文字化:     |  ボリューム (24 時間):